Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

zentiva k.s. - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

ever valinject gmbh - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

sun pharmaceutical industries europe bv - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

tillomed pharma gmbh - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

European Union - Danish - EMA (European Medicines Agency)

sandoz gmbh - epoetin alfa - anemia; kidney failure, chronic - antianemiske præparater - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. hjerte-kar-status, præ-eksisterende anæmi ved start af kemoterapi).

European Union - Danish - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - adalimumab - hidradenitis suppurativa; psoriasis; uveitis; arthritis, rheumatoid; spondylitis, ankylosing; crohn disease; colitis, ulcerative; arthritis, psoriatic - immunosuppressants, tumor nekrose faktor alfa (tnf-α) - hæmmere